Lupin said that it has received the establishment inspection report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India, with a 'voluntary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback